Several biotech and pharma companies attend healthcare
conferences where they get an opportunity to showcase their
pipeline and product portfolio. These conferences also give
investors a chance to know more about the company and the
potential catalysts that could impact the share price.
Earlier this week,
) attended the Piper Jaffray Healthcare Conference and provided
an insight on its pipeline and future plans.
Xyrem for narcolepsy, the lead product at Jazz Pharma, continues
to exhibit an impressive performance. Xyrem sales increased 50%
to $153.7 million in the third quarter of 2013. On an average,
volume growth of 12%-15% has been witnessed in the last four
To further boost Xyrem revenues, the company has expanded the
sales force. To reach out to more physicians, Jazz Pharma has
decided to expand the narcolepsy sales force from 80 territories
to 100 territories. Xyrem net sales in 2013 are expected in the
range of $565-$570 million as compared to $378.7 million in 2012.
However, Jazz Pharma is also facing a series of patent challenges
on Xyrem. Three companies including Roxane Laboratories, Inc. are
looking to market their versions of generic Xyrem and have filed
abbreviated New Drug Application (ANDA) for the same. Existing
patents protecting Xyrem expire between 2019 and 2024.
To protect its revenues, the company is developing JZP-386, a
deuterated version of sodium oxybate (the drug in Xyrem). The
company plans to move the candidate into human trials in 2014.
Apart from Xyrem, Erwinaze, an oncology drug, has also been
performing well. In the third quarter of 2013, Erwinaze generated
revenues of $44.1 million, up 39% year over year. For 2013,
Erwinaze net sales are expected to be approximately $175 million
compared with $72.1 million in the prior year.
For 2013, Jazz Pharma expects revenue in the range of $867-$877
million and adjusted earnings in the range of $6.30 to $6.40 per
share. The Zacks Consensus Estimate currently stands at $5.77 per
The Zacks Consensus Estimate for 2013 increased 10 cents over
the last 30 days on the back of positive estimate revisions. For
2014, estimates were revised higher over the same time frame,
lifting the Zacks Consensus Estimate by 43 cents to $7.78 per
AETERNA ZENTARS (AEZS): Free Stock Analysis
ACTELION LTD (ALIOF): Get Free Report
JAZZ PHARMACEUT (JAZZ): Free Stock Analysis
QUESTCOR PHARMA (QCOR): Free Stock Analysis
To read this article on Zacks.com click here.
Jazz Pharma carries a Zacks Rank #1 (Strong Buy). Other players
which look attractive at current levels, include
Aeterna Zentaris Inc.
Questcor Pharmaceuticals Inc.
). All these stocks carry the same Zacks Rank as Jazz Pharma.